Eli Lilly & Co (LLY) Stock Forecast & Price Target
3 Followers
LLY Analyst Ratings
Strong Buy
22Buy1Hold1Sell
Based on 24 analysts giving stock ratings to Eli Lilly & Co in the past 3 months
LLY Stock 12 Month Forecast
Average Price Target
CHF 1,230.60â–²(9.87% Upside)Based on 24 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is CHF 1,230.60 with a high forecast of CHF 1,343.53 and a low forecast of CHF 765.41. The average price target represents a 9.87% change from the last price of CHF 1,120.00.
Past 12 Months12 Month ForecastJan2026Oct2026
HighCHF 1.34K
AverageCHF 1.23K
LowCHF 765.41
Highest Price TargetHighestCHF 1,343.53Average Price TargetCHF 1,230.60Lowest Price TargetLowestCHF 765.41
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Jason Gerberry | Bank of America Securities | CHF 1,218.95→CHF 1,267.80 | buy | 13.20%Upside | Reiterated | 11/05/26 | ||
| Evan Seigerman | BMO Capital | CHF 1,139.96→CHF 1,343.53 | buy | 19.96%Upside | Reiterated | 11/02/26 | ||
| David Risinger | Leerink Partners | CHF 1,071.57→CHF 1,227.91 | buy | 9.63%Upside | Reiterated | 11/02/26 | ||
| Carter Gould | Cantor Fitzgerald | CHF 1,172.54→CHF 1,302.82 | buy | 16.32%Upside | Reiterated | 11/01/26 | ||
| Geoff Meacham | Citi | CHF 1,302.82→CHF 1,343.53 | buy | 19.96%Upside | Reiterated | 10/30/26 | ||
| Michael Yee | UBS | CHF 1,160.32→CHF 1,323.17 | buy | 18.14%Upside | Assigned | 10/30/26 | ||
| Chris Schott | J.P. Morgan | CHF 1,221.39→CHF 1,343.53 | buy | 19.96%Upside | Assigned | 10/30/26 | ||
| Louise Chen | Scotiabank | CHF 1,058.54→CHF 1,306.89 | buy | 16.69%Upside | Reiterated | 10/30/26 | ||
| Jasper Hellweg | Argus Research | CHF 1,058.54→CHF 1,262.10 | buy | 12.69%Upside | Reiterated | 10/30/26 | ||
| Asad Haider | Goldman Sachs | CHF 1,150.55→CHF 1,280.83 | buy | 14.36%Upside | Assigned | 10/30/26 | ||
| Srikripa Devarakonda | Truist Financial | CHF 1,120.42→CHF 1,312.59 | buy | 17.20%Upside | Reiterated | 10/30/26 | ||
| Terence Flynn | Morgan Stanley | CHF 1,164.39→CHF 1,299.56 | buy | 16.03%Upside | Reiterated | 10/30/26 | ||
| Ilya Zubkov | Freedom Capital Markets | CHF 1,139.96→CHF 1,302.82 | buy | 16.32%Upside | Reiterated | 10/30/26 | ||
| Emily Field | Barclays | CHF 1,139.96 | buy | 1.78%Upside | Reiterated | 10/29/26 | ||
| Akash Tewari | Jefferies | CHF 1,172.54→CHF 1,310.96 | buy | 17.05%Upside | Assigned | 10/29/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Jason GerberryBank of America Securities | BuyReiteratedCHF 1,218.95→CHF 1,267.80 | 11/05/26 | 13.20%Upside | ||
| Evan SeigermanBMO Capital | BuyReiteratedCHF 1,139.96→CHF 1,343.53 | 11/02/26 | 19.96%Upside | ||
| David RisingerLeerink Partners | BuyReiteratedCHF 1,071.57→CHF 1,227.91 | 11/02/26 | 9.63%Upside | ||
| Carter GouldCantor Fitzgerald | BuyReiteratedCHF 1,172.54→CHF 1,302.82 | 11/01/26 | 16.32%Upside | ||
| Geoff MeachamCiti | BuyReiteratedCHF 1,302.82→CHF 1,343.53 | 10/30/26 | 19.96%Upside | ||
| Michael YeeUBS | BuyAssignedCHF 1,160.32→CHF 1,323.17 | 10/30/26 | 18.14%Upside | ||
| Chris SchottJ.P. Morgan | BuyAssignedCHF 1,221.39→CHF 1,343.53 | 10/30/26 | 19.96%Upside | ||
| Louise ChenScotiabank | BuyReiteratedCHF 1,058.54→CHF 1,306.89 | 10/30/26 | 16.69%Upside | ||
| Jasper HellwegArgus Research | BuyReiteratedCHF 1,058.54→CHF 1,262.10 | 10/30/26 | 12.69%Upside | ||
| Asad HaiderGoldman Sachs | BuyAssignedCHF 1,150.55→CHF 1,280.83 | 10/30/26 | 14.36%Upside | ||
| Srikripa DevarakondaTruist Financial | BuyReiteratedCHF 1,120.42→CHF 1,312.59 | 10/30/26 | 17.20%Upside | ||
| Terence FlynnMorgan Stanley | BuyReiteratedCHF 1,164.39→CHF 1,299.56 | 10/30/26 | 16.03%Upside | ||
| Ilya ZubkovFreedom Capital Markets | BuyReiteratedCHF 1,139.96→CHF 1,302.82 | 10/30/26 | 16.32%Upside | ||
| Emily FieldBarclays | BuyReiteratedCHF 1,139.96 | 10/29/26 | 1.78%Upside | ||
| Akash TewariJefferies | BuyAssignedCHF 1,172.54→CHF 1,310.96 | 10/29/26 | 17.05%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Eli Lilly & Co
3 Months
Success Rate30/38 ratings generated profit
79%
Average Return
+10.03%
Copying Louise Chen's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +10.03% per trade.
1 Year
Success Rate43/44 ratings generated profit
98%
Average Return
+46.52%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 97.73% of your transactions generating a profit, with an average return of +46.52% per trade.
2 Years
Success Rate49/49 ratings generated profit
100%
Average Return
+81.60%
Copying Terence Flynn's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +81.60% per trade.
LLY Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 2 | 0 | 0 | 0 | 0 |
| Buy | 76 | 70 | 66 | 79 | 58 |
| Hold | 3 | 4 | 4 | 3 | 1 |
| Sell | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 81 | 74 | 71 | 83 | 60 |
In the current month, LLY has received 58 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. LLY average Analyst price target in the past 3 months is 1,230.60.
LLY Financial Forecast
HighCHF 10.15
ConsensusCHF 9.15
LowCHF 8.47
LLY Earnings Forecast
Next quarter’s earnings estimate for LLY is CHF 9.15 with a range of CHF 8.47 to CHF 10.15. The previous quarter’s EPS was CHF 6.11. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighCHF 21.1B
ConsensusCHF 20.1B
LowCHF 19.1B
LLY Sales Forecast
Next quarter’s sales forecast for LLY is CHF 20.09B with a range of CHF 19.11B to CHF 21.08B. The previous quarter’s sales results were CHF 19.93B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
LLY Stock Forecast FAQ
What is CH:LLY’s average 12-month price target, according to analysts?
Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is CHF1,230.60.
What is CH:LLY’s upside potential, based on the analysts’ average price target?
Eli Lilly & Co has 9.87% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Eli Lilly & Co a Buy, Sell or Hold?
Eli Lilly & Co has a consensus rating of Strong Buy, which is based on 22 buy ratings, 1 hold ratings and 1 sell ratings.
What is Eli Lilly & Co’s share price target?
The average share price target for Eli Lilly & Co is CHF1,230.60. This is based on 24 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF1,343.53, and the lowest forecast is CHF765.41. The average share price target represents a 9.87% increase from the current price of CHF1,120.
What do analysts say about Eli Lilly & Co?
Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Street analysts.
How can I buy shares of Eli Lilly & Co?
To buy shares of CH:LLY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
